# SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

> **NCT06457906** · PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 340 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Brain Metastases
- SRS
- Stereotactic Radiotherapy
- Whole Brain Radiotherpay
- Hippocampal-avoidance

## Interventions

- **COMBINATION_PRODUCT:** Experimental group (SRS/SRT/Hypo-RT)
- **RADIATION:** Controled group (HA-WBRT)

## Key facts

- **NCT ID:** NCT06457906
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06457906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06457906, "SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06457906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*